<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04727502</url>
  </required_header>
  <id_info>
    <org_study_id>AP2007-50104</org_study_id>
    <nct_id>NCT04727502</nct_id>
  </id_info>
  <brief_title>Comparison of Duloxetine Versus Pregabalin</brief_title>
  <official_title>Comparison of Duloxetine Versus Pregabalin in Post-mastectomy Pain Syndrome: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute, Egypt</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute, Egypt</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic post mastectomy pain syndrome (PMPS) is a chronic post-surgical neuropathic pain&#xD;
      following breast cancer surgeries and lasting more than three months after surgeries.&#xD;
      Pregabalin is originally used as an antiepileptic drug and identiﬁed as treatment for&#xD;
      neuropathic pain .There are several recent reviews have revealed that it reduces&#xD;
      post-operative opioid consumption and improves pain scores after breast surgeries. Duloxetine&#xD;
      is a serotonin and norepinephrine reuptake inhibitor. Its mechanism of action is related to&#xD;
      the potentiation of serotonergic and noradrenergic activity in the descending inhibitory pain&#xD;
      pathways of the central nervous system and used for treatment of neuropathic pain conditions&#xD;
      as painful diabetic neuropathy, neuropathic pain of lung cancer and chemotherapy induced&#xD;
      sensory neuropathy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with of 3 months of chronic neuropathic pain after breast surgery (either modified&#xD;
      radical mastectomy or conservative breast surgery) combined with axillary dissection is&#xD;
      considered as post mastectomy pain syndrome which is defined as pain involving the anterior&#xD;
      aspect of the chest, axilla, and/or upper arm with the classical features of neuropathic pain&#xD;
      including numbness, tingling, burning, shooting, stinging, or stabbing pains, and&#xD;
      hyperesthesia.&#xD;
&#xD;
        -  They are divided to 2 equal groups: ( Group A) receive duloxetine for 12 weeks and&#xD;
           (Group B) control group receive pregabalin for 12 weeks .&#xD;
&#xD;
        -  Dosing and administration Group A) Duloxetine 30 mg /day at bed time and (Group B)&#xD;
           control group Pregablin 150mg /day( 75 mg /12 hours )&#xD;
&#xD;
        -  Randomization and blinding: Randomization is done using computer generated sequence.&#xD;
           Concealment will be achieved by opaque envelope.&#xD;
&#xD;
        -  Concomitant therapy :opioid therapy according to WHO step ladder in cancer pain&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 20, 2020</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>2 equal groups ( Group A) :receive duloxetine for 12 weeks and (Group B) control group receive pregabalin for 12 weeks .&#xD;
• Dosing and administration Group A) Duloxetine 30 mg /day at bed time and (Group B) control group Pregablin 150mg /day( 75 mg /12 hours</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Care Provider, Outcomes Assessor)</masking>
    <masking_description>Randomization is done using computer generated sequence. Concealment will be achieved by opaque envelope.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>visual analogue score</measure>
    <time_frame>baseline till 12 weeks of treatment</time_frame>
    <description>visual analogue score with least pain score is 0 and worst pain is 10</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Drug Effect</condition>
  <arm_group>
    <arm_group_label>( Group Duloxetine )</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>• Dosing and administration (Group A) Duloxetine 30 mg /day oral intake at bed time</description>
  </arm_group>
  <arm_group>
    <arm_group_label>(Group Pregablin )</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>control group Pregablin 150mg /day( 75 mg /12 hours ) oral intake.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duloxetine</intervention_name>
    <description>duloxetine</description>
    <arm_group_label>( Group Duloxetine )</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregablin</intervention_name>
    <description>Pregablin</description>
    <arm_group_label>(Group Pregablin )</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female, history of breast surgery and patients with post mastectomy pain&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pregnancy,history of allergy to Pregabalin or duloxetine, pregnancy or lactation,&#xD;
             history of pregabalin or gabapentin intake in the preceding three months, history of&#xD;
             radiotherapy and history of drug abuse&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Adult female patients underwent breast cancer surgeries presented with post mastectomy pain syndrome</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed Abdel Wadod, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute - Cairo University - Egypt</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mohamed Abdel Wadod, MD</last_name>
    <phone>+201006645981</phone>
    <email>m_wadod@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wala yousef, Md</last_name>
    <phone>+201007798466</phone>
    <email>wala_70s@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nataional Cancer Instituite</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>mohamed Abdel Wadod, MD</last_name>
      <phone>+201006645981</phone>
      <email>m_wadod@yahoo.coll</email>
    </contact>
    <contact_backup>
      <last_name>Wala Yousef, MD</last_name>
      <phone>+201007798466</phone>
      <email>wala_70s@hotmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 25, 2020</study_first_submitted>
  <study_first_submitted_qc>January 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2021</study_first_posted>
  <last_update_submitted>January 26, 2021</last_update_submitted>
  <last_update_submitted_qc>January 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Cancer Institute, Egypt</investigator_affiliation>
    <investigator_full_name>Mohammed Abdelfattah Abdelwadod</investigator_full_name>
    <investigator_title>Mohammed Abdelfattah Abdelwadod</investigator_title>
  </responsible_party>
  <keyword>pregabalin and Duloxetine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Duloxetine Hydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

